Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

The determination of liver fibrosis showed stage F0 in 29, F1 in 39, 34 patients in F2 and F3 stage each and 21 patients in F4 or advanced fibrosis leading to cirrhosis.

Waist-to-height ratio had a better predictive value than BMI in assessing liver fibrosis and steatosis outcomes across ages and racial groups.

In this case, I was right, in that it was shown that these F4 fibrosis compensated cirrhosis MASH patients needed to be treated with EFX for a longer duration. With that said, ...

The cohort included 405 patients. Table 1 shows the patient characteristics at the time of liver biopsy. The training and validation sets did not significantly differ in any of the assessed ...

- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis stage 4 at baseline (putative F4); excluding these patients resulted in ...

Results also showed that MASH resolution, regardless of fibrosis, occurred in about 80% of the cohort, and improvement of fibrosis from stage F2 to F4 to F0 to F1 correlated with longer 15-year ...

After these F4 compensated cirrhosis MASH patients were given efruxifermin over a 96-week period, it was shown that the drug actually did help these patients achieve an improvement in fibrosis ...

—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24 ...

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

In addition, the rate of Americans with F3/F4 fibrosis or advanced liver cancer is likely to outpace that of other countries, growing from 21% of the 2016 NASH population to 29% of cases, a projected ...